Zuzanna Witkowska

Zuzanna Witkowska

Auto-generated profile, based on publicly available information

Zuzanna Witkowska

Szpital Praski p.w. Przemienienia Pańskiego, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AKAlicja Komorowska
Alicja Komorowska
MRMartyna Rutka
Martyna Rutka
JKJakub Kądziela
Jakub Kądziela
GSGabriela Soćko
Gabriela Soćko
BJBarbara JastrzęBska
Barbara JastrzęBska
BRBartosz Rutka
Bartosz Rutka
Background: Vein of Galen aneurysmal malformations (VGAMs) represent a complex and rare subset of congenital arteriovenous anomalies, comprising approximately 30% of all pediatric cerebral vascular malformations. Originating during early embryogenesis between the 6th and 11th weeks of gestation, these lesions create a low-resistance, high-flow shunt. Consequently, they frequently precipitate life-threatening complications, most notably high-output heart failure and severe neurological compromise in the immediate postnatal period, necessitating prompt and accurate diagnostic strategies. Aim: The primary objective of this study is to elucidate the critical, first-line diagnostic and monitoring role of bedside transfontanellar ultrasonography in the management of neonatal VGAMs. Additionally, we aim to contextualize these clinical findings within a comprehensive review of the current literature, emphasizing recent paradigm shifts in neurointensive care and endovascular therapies. Material and methods: We report the clinical case of a 4-week-old male newborn admitted to the emergency department with recurrent generalized seizures, progressive macrocephaly, and profound perioral cyanosis. A detailed clinical evaluation was conducted, prioritizing bedside neurosonography. This clinical presentation is supplemented by a comprehensive literature review exploring the evolving landscape of VGAM management, including molecular genetics and fetal interventions. Results: Urgent transfontanellar ultrasonography augmented by color Doppler identified a prominent hypoechoic arteriovenous malformation demonstrating high-velocity turbulent flow. This was accompanied by secondary findings of lateral ventricle dilatation and diffuse parenchymal calcifications indicative of chronic ischemic injury. The precise neurovascular architecture was subsequently verified via Magnetic Resonance Imaging (MRI). Following multidisciplinary conservative management to allow for infant growth, the patient successfully underwent transarterial embolization at 7 months of age. A follow-up ultrasound at 9 months confirmed a significant reduction in arteriovenous shunting and stabilization of the cerebral structures. Conclusions: Bedside transfontanellar ultrasonography serves as an indispensable, non-invasive, and radiation-free modality for the rapid identification, hemodynamic profiling, and serial follow-up of VGAMs in critically ill neonates. Its integration with advanced, staged endovascular techniques and emerging prenatal in utero interventions fundamentally transforms the clinical trajectory of this historically fatal congenital defect.

21 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ZOZuzanna Ostrowska
Zuzanna Ostrowska
ZWZuzanna Witkowska
Zuzanna Witkowska
BRBartosz Rutka
Bartosz Rutka
BJBarbara Maria JastrzęBska
Barbara Maria JastrzęBska
ADAlicja Danieluk
Alicja Danieluk
AKAlicja Komorowska
Alicja Komorowska
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent inflammation of the colon resulting from immune dysregulation. Despite the availability of multiple therapeutic options, a substantial proportion of patients fail to achieve sustained remission or develop loss of response to existing therapies. Increasing evidence has identified the interleukin-23 (IL-23)/Th17 pathway as a key mechanism involved in the pathogenesis of UC, leading to the development of selective IL-23 inhibitors as novel therapeutic agents. Purpose: The aim of this study was to review and summarize current evidence regarding the efficacy and safety of IL-23 inhibitors, particularly mirikizumab, risankizumab and guselkumab, in the treatment of moderate-to-severe ulcerative colitis. Methodology: A narrative literature review was performed using PubMed and ClinicalTrials.gov to identify relevant studies investigating IL-23 inhibitors in the treatment of ulcerative colitis. The review included phase II and phase III randomized controlled trials, long term extension studies, real-world observational cohorts, systematic reviews and meta-analyses. Data were extracted and synthesized to provide a comprehensive assessment of the efficacy, safety and evolving therapeutic role of IL-23 inhibitors in ulcerative colitis. Conclusions: Available evidence indicates that IL-23 inhibitors are effective therapeutic options for patients with moderate-to-severe ulcerative colitis. Mirikizumab, risankizumab and guselkumab demonstrated significant improvements in clinical remission, endoscopic healing, histologic outcomes and quality of life. Among these agents, mirikizumab currently has the strongest evidence supporting long-term efficacy and durability of response. IL-23 inhibitors also demonstrated favorable safety profiles, with low rates of serious adverse events and treatment discontinuation. Although further real-world data and head-to-head comparative studies are still needed, selective IL-23 blockade represents a promising advancement in personalized UC treatment strategies.

21 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ZWZuzanna Witkowska
Zuzanna Witkowska
ZOZuzanna Ostrowska
Zuzanna Ostrowska
OPOskar Paprocki
Oskar Paprocki
BRBartosz Rutka
Bartosz Rutka
BJBarbara JastrzęBska
Barbara JastrzęBska
AKAlicja Komorowska
Alicja Komorowska
Introduction: Pain remains one of the most prevalent health problems worldwide and a major cause of disability, reduced quality of life and healthcare utilization. Although opioid analgesics have long been considered the cornerstone of treatment for moderate-to-severe pain, their use is associated with substantial risks, including tolerance, dependence, addiction and overdose. Consequently, the development of effective non-opioid analgesics has become a priority in pain medicine. Suzetrigine (VX-548), a selective voltage-gated sodium channel NaV1.8 inhibitor, has recently emerged as a promising therapeutic option for acute pain management. Purpose: The aim of this review is to evaluate the current evidence regarding suzetrigine as a novel non-opioid analgesic and to discuss its potential role in the future of pain management. Particular attention is given to the clinical burden of pain, the limitations of existing analgesic therapies, the biological rationale for targeting NaV1.8 channels, and the efficacy and safety of suzetrigine. Methodology: A narrative review of literature was conducted using published preclinical studies, clinical trials, review articles, systematic reviews and meta-analyses concerning suzetrigine and NaV1.8 inhibition using PubMed and Clinicaltrials.gov. The reviewed literature included studies evaluating pharmacological properties, mechanism of action, clinical efficacy, safety profile and potential therapeutic applications of suzetrigine in acute and chronic pain conditions. Conclusion: Current evidence indicates that suzetrigine represents a significant advancement in analgesic drug development. By selectively inhibiting NaV1.8 channels involved in peripheral nociceptive signaling, it provides effective pain relief without engaging opioid pathways. Clinical studies have demonstrated favorable efficacy and tolerability in patients, with moderate-to-severe acute pain, while ongoing research continues to explore its potential applications in chronic and disease-specific pain conditions. Suzetrigine may therefore contribute to reducing reliance on opioid analgesics and represents a promising step toward safer pain management strategies.